As reminded above, downregulation of the major metabolic regulator AMPK in obesity plays a relevant role in the maintenance of a low-grade inflammation in adipose and other tissues, so that the use of AMPK activating agents has long been considered a promising approach for prevention or treatment of metabolic diseases. Here, PRKAA1 is linked to Other metabolic disease.